



<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	10/700,333
	<b>Filing Date</b>	November 3, 2003
	<b>First Named Inventor</b>	Mark Ledebor
	<b>Group Art Unit</b>	1624
	<b>Examiner Name</b>	Venkataraman Balasubramanian
	<b>Attorney Docket Number</b>	VPI/02-116 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date/ Publication date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
M	A1	US2004/0176271 A1	September 9, 2004	Vertex Pharmaceuticals Incorporated	514	2	11/5/2003

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
M	B6	WO 03/030909 A1	Bayer Corporation	17 April 2003		
M	B7	WO 02/079193 A1	Cyclacel Limited	10 October 2002		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

<b>Examiner Signature</b>	<i>V. Balasubramanian</i>	<b>Date Considered</b>	3/19/07
---------------------------	---------------------------	------------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

RECEIVED  
CENTRAL FAX CENTER

042/065

DEC 21 2006

Modified Form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/700,333
	Filing Date	November 2, 2003
	First Named Inventor	Mark Ledebner
	Group Art Unit	1624
	Examiner Name	Venkataraman Balasubramanian
	Attorney Docket Number	VPI/02-116 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Publication Date/ Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate


FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
M	C1	Chang et al., "Prevention of organ allograft rejection by a specific janus kinase 3 inhibitor," Science, 302:875-878, (2003).
M	C2	Malaviya et al., "Treatment of allergic asthma by targeting Janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3',5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97)," The Journal of Pharmacology and Experimental Therapeutics, 295(3):912-926, (2000).
M	C3	Trieu et al., "A specific inhibitor of Janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis," Biochemical and Biophysical Research Communications, 267:22-25, (2000).

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	V Balasubramanian	Date Considered	3/19/07
--------------------	-------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	Application Number	10/700,333
	Filing Date	November 3, 2003
	First Named Inventor	Mark Ledebuer
	Group Art Unit	1624
	Examiner Name	Venkataraman Balasubramanian
	Attorney Docket Number	VPI02-116 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date/ Publication Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
V/B	A2	6,949,544	September 27, 2005	Vertex Pharmaceuticals Incorporated	514	235.8	March 28, 2002

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Office	Patent Document Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
V/B	B8	WO	02/22601	Vertex Pharmaceuticals Incorporated	21 March 2002		
V/B	B9	WO	99/65897	Chiron Corporation	23 December 1999		
V/B	B10	WO	95/09851	Ciba-Geigy AG	13 April 1995		
V/B	B11	WO	95/09847	Ciba-Geigy AG	13 April 1995		
V/B	B12	WO	95/09853	Ciba-Geigy AG	13 April 1995		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	V Balasubramanian	Date Considered	3/19/07
--------------------	-------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.